{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:13:43Z","timestamp":1757700823653},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/s11886-004-0012-0","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T07:48:03Z","timestamp":1180165683000},"page":"135-142","source":"Crossref","is-referenced-by-count":2,"title":["The role of warfarin and aspirin in secondary prevention of stroke"],"prefix":"10.1007","volume":"6","author":[{"given":"Mitchell S. V.","family":"Elkind","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983\u2013988.","journal-title":"Stroke"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"1","author":"P Petersen","year":"1989","unstructured":"Petersen P, Boysen G, Gotfredsen J, et al.: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989, 1:175\u2013179.","journal-title":"Lancet"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","volume":"323","author":"Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators","year":"1990","unstructured":"Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators: The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990, 323:1505\u20131511.","journal-title":"N Engl J Med"},{"key":"12_CR4","first-page":"687","volume":"343","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1994","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687\u2013691.","journal-title":"Lancet"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","volume":"342","author":"European Atrial Fibrillation Trial Study Group","year":"1993","unstructured":"European Atrial Fibrillation Trial Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255\u20131262.","journal-title":"Lancet"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1991","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators: Stroke prevention in atrial fibrillation study, final results. Circulation 1991, 84:527\u2013539.","journal-title":"Circulation"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","volume":"348","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1996","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators: Adjusteddose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633\u2013638.","journal-title":"Lancet"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-5223(19)38673-8","volume":"90","author":"EM Baudet","year":"1985","unstructured":"Baudet EM, Oca CC, Roques XF, et al.: A 5 1\/2 year experience with the St. Jude Medical cardiac valve prosthesis. Early and late results of 737 valve replacements in 671 patients. J Thorac Cardiovasc Surg 1985, 90:137\u2013144.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM199701233360403","volume":"336","author":"E Loh","year":"1997","unstructured":"Loh E, Sutton MSJ, Wun CC, et al.: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997, 336:251\u2013257.","journal-title":"N Engl J Med"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.STR.30.9.1991","volume":"30","author":"PA Wolf","year":"1999","unstructured":"Wolf PA, Clagett GP, Easton JD, et al.: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999, 30:1991\u20131994.","journal-title":"Stroke"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"300S","DOI":"10.1378\/chest.119.1_suppl.300S","volume":"119","author":"GW Albers","year":"2001","unstructured":"Albers GW, Amarenco P, Easton JD, et al.: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001, 119:300S-320S. This excellent review provides a comprehensive analysis of the use of antithrombotic therapies in acute stroke and stroke prevention.","journal-title":"Chest"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr JP, Thompson JLP, Lazar RM, et al., for the Warfarin-Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444\u20131451. This paper provides the final results of the landmark WARSS study regarding the relative benefits and risks of warfarin versus aspirin in secondary prevention of stroke.","journal-title":"N Engl J Med"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.CIR.0000017498.88393.44","volume":"105","author":"S Homma","year":"2002","unstructured":"Homma S, Sacco RL, Di Tullio MR, et al.: Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002, 105:2625\u20132631. This paper provides the final results of the PICSS substudy of WARSS, which addressed the role of warfarin versus aspirin in patients with a history of ischemic stroke and PFO. The paper provides evidence that PFO may be associated with cryptogenic stroke, but did not demonstrate an effect of PFO on stroke recurrence risk, nor a role for warfarin over aspirin in this setting.","journal-title":"Circulation"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","unstructured":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997, 42:857\u2013865.","journal-title":"Ann Neurol"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198805053181802","volume":"318","author":"P Lechat","year":"1988","unstructured":"Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148\u20131152.","journal-title":"N Engl J Med"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-117-6-461","volume":"117","author":"M Tullio Di","year":"1992","unstructured":"Di Tullio M, Sacco RL, Gopal A, et al.: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992, 117:461\u2013465.","journal-title":"Ann Intern Med"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMoa011503","volume":"345","author":"JL Mas","year":"2001","unstructured":"Mas JL, Arquizan C, Lamy C, et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740\u20131746.","journal-title":"N Engl J Med"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.45.8.1488","volume":"45","author":"MI Chimowitz","year":"1995","unstructured":"Chimowitz MI, Kokkinos J, Strong J, et al.: The Warfarin-Aspirin Symptomatic Intracranial Disease study. Neurology. 1995, 45:1488\u20131493.","journal-title":"Neurology."},{"key":"12_CR19","first-page":"e46","volume":"34","author":"ESPRIT Study Group","year":"2003","unstructured":"ESPRIT Study Group: Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003, 34:e46-e47.","journal-title":"Stroke"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","volume":"299","author":"The Canadian Cooperative Study Group","year":"1978","unstructured":"The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978, 299:53\u201359.","journal-title":"N Engl J Med"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","volume":"338","author":"The SALT Collaborative Group","year":"1991","unstructured":"The SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991, 338:1345\u20131349.","journal-title":"Lancet"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurolog Sci 1996, 143:1\u201313.","journal-title":"J Neurolog Sci"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","volume":"325","author":"The Dutch TIA Trial Study Group","year":"1991","unstructured":"The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261\u20131266.","journal-title":"N Engl J Med"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","volume":"54","author":"B Farrell","year":"1991","unstructured":"Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044\u20131054.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","volume":"i","author":"M Gent","year":"1989","unstructured":"Gent M, Blakely JA, Easton JD, et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, i:1215\u20131220.","journal-title":"Lancet"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","volume":"321","author":"WK Hass","year":"1989","unstructured":"Hass WK, Easton JD, Adams HP Jr., et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989, 321:501\u2013507.","journal-title":"N Engl J Med"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","volume":"289","author":"PB Gorelick","year":"2003","unstructured":"Gorelick PB, Richardson D, Kelly M, et al.: African American Antiplatelet Stroke Prevention study investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003, 289:2947\u20132957.","journal-title":"JAMA"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"The CAPRIE Steering Committee","year":"1996","unstructured":"The CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329\u20131339.","journal-title":"Lancet"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","volume":"342","author":"CL Bennett","year":"2000","unstructured":"Bennett CL, Connors JM, Carwile JM, et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773\u20131777.","journal-title":"N Engl J Med"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators","year":"2001","unstructured":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494\u2013502.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-004-0012-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0012-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:36:17Z","timestamp":1587555377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-004-0012-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11886-004-0012-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}